Pyxis Oncology (NASDAQ:PYXS – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Pyxis Oncology to related businesses based on the strength of its dividends, analyst recommendations, profitability, earnings, institutional ownership, risk and valuation.
Institutional & Insider Ownership
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Pyxis Oncology has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Pyxis Oncology’s peers have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.
Profitability
This table compares Pyxis Oncology and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pyxis Oncology | N/A | -215.23% | -112.19% |
| Pyxis Oncology Competitors | -9,051.23% | -201.20% | -30.64% |
Valuation & Earnings
This table compares Pyxis Oncology and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Pyxis Oncology | $13.86 million | -$79.62 million | -1.18 |
| Pyxis Oncology Competitors | $720.15 million | $12.21 million | -10.20 |
Pyxis Oncology’s peers have higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of current ratings and target prices for Pyxis Oncology and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pyxis Oncology | 1 | 0 | 7 | 0 | 2.75 |
| Pyxis Oncology Competitors | 9789 | 15070 | 45344 | 1572 | 2.54 |
Pyxis Oncology presently has a consensus price target of $9.00, indicating a potential upside of 442.17%. As a group, “Biotechnology” companies have a potential upside of 93.62%. Given Pyxis Oncology’s stronger consensus rating and higher possible upside, equities analysts clearly believe Pyxis Oncology is more favorable than its peers.
Summary
Pyxis Oncology peers beat Pyxis Oncology on 7 of the 12 factors compared.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
